GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.

Blenrep [package insert]. Brentford, Middlesex, UK; GlaxoSmithKline, Ltd; August 2020. Accessed August 2020. 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for belantamab mafodotin. National Comprehensive Cancer Network, 2020.

Dosage form: Injection. Company: GlaxoSmithKline. Treatment for: Multiple Myeloma. Blenrep (belantamab mafodotin-blmf) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor 2020-01-21 Package insert. GlaxoSmithKline; 2020. Lonial S, Lee HC, Badros A, et al.

Treatment for: Multiple Myeloma.

BLENREP (belantamab mafodotin-blmf) for injection is a sterile, preservative-free, white to yellow lyophilized powder for reconstitution and further dilution prior to intravenous use. BLENREP is supplied in a carton containing one 100-mg single-dose vial with a rubber stopper (not made with natural rubber latex) and aluminum overseal with removable cap ( NDC 01730896-01).

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. 2,5 Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Generic name: belantamab mafodotin-blmf Dosage form: Injection Company: GlaxoSmithKline Treatment for: Multiple Myeloma.

In Part 2 of the trial patients received belantamab mafodotin 3.4 mg/kg once every 3 weeks for up to 16 cycles (~1 year). Overall, the scientists observed that belantamab mafodotin was well tolerated and demonstrated rapid deep and durable responses in heavily pre-treated patients with patients with relapsed/refractory multiple myeloma.

The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL BELANTAMAB MAFODOTIN-BLMF: 2.5MG/KG: INJECTABLE;INTRAVENOUS: Prescription: None No: No BLENREP is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines to treat multiple myeloma, and their cancer has come back or did not respond to prior treatment.

National Comprehensive Cancer Network, 2020. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL BELANTAMAB MAFODOTIN-BLMF: 2.5MG/KG: INJECTABLE;INTRAVENOUS: Prescription: None No: No BLENREP is a prescription medicine used to treat adults with multiple myeloma who have received at least 4 prior medicines to treat multiple myeloma, and their cancer has come back or did not respond to prior treatment. It is not known if BLENREP is safe and effective in children. BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. 2,5 Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism.
Ivf sahlgrenska 2021

FDA Approved: Yes (First approved August 5, 2020) Brand name: Blenrep.

644 belantamab mafodotine immunoglobuline G1-kappa, anti-[Homo used belantamab, which is an antibody drug conjugate targeting the BCMA We don't know where the best place is to insert it in the treatment package. BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use Initial U.S. Approval: 2020 .
Falun lugnet mtb

Jan 19, 2018 Proposed INN: List 118. WHO Drug Information, Vol. 31, No. 4, 2017. 644 belantamab mafodotine immunoglobuline G1-kappa, anti-[Homo

The NCCN Compendium® is a derivative work of the NCCN Guidelines 1. Blenrep [package insert]. Brentford, Middlesex, UK; GlaxoSmithKline, Ltd; August 2020.

Amazon tyskland til danmark

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone (BVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Robert Rifkin,1Kevin Boyd,2Sebastian Grosicki,3Kihyun Kim,4Francesco Di Raimondo,5Meletios Dimopoulos,6Katja Weisel,7Bertrand Arnulf,8Roman Hajek,9Vania

Patients can click here to locate providers of Belantamab Mafodotin (BLENREP®). DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone (BVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Robert Rifkin,1Kevin Boyd,2Sebastian Grosicki,3Kihyun Kim,4Francesco Di Raimondo,5Meletios Dimopoulos,6Katja Weisel,7Bertrand Arnulf,8Roman Hajek,9Vania Find patient medical information for belantamab mafodotin-blmf intravenous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Belantamab mafodotin-blmf (Blenrep) has elicited significant responses in patients with relapsed/refractory multiple myeloma, but the corneal toxicities associated with its use will require a 2020-06-04 Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. This indication is approved under accelerated approval based on response rate. The NLM Drug Information Portal gives users a gateway to selected drug information from the National Library of Medicine and other key government agencies. More than 49,000 drugs can be searched.